Dexxon Holdings Ltd. - Net Worth and Insider Trading
Dexxon Holdings Ltd. Net Worth
The estimated net worth of Dexxon Holdings Ltd. is at least $1.5 Billion dollars as of 2024-04-23. Dexxon Holdings Ltd. is the 10% Owner of Myovant Sciences Ltd and owns about 40,765,599 shares of Myovant Sciences Ltd (MYOV) stock worth over $1.1 Billion. Dexxon Holdings Ltd. is the 10% Owner of Urovant Sciences Ltd and owns about 22,860,013 shares of Urovant Sciences Ltd (UROV) stock worth over $371 Million. Dexxon Holdings Ltd. is also the 10% Owner of Sio Gene Therapies Inc and owns about 13,244,048 shares of Sio Gene Therapies Inc (SIOX) stock worth over $6 Million. Details can be seen in Dexxon Holdings Ltd.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Dexxon Holdings Ltd. has not made any transactions after 2019-06-19 and currently still holds the listed stock(s).
Transaction Summary of Dexxon Holdings Ltd.
Dexxon Holdings Ltd. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Dexxon Holdings Ltd. owns 5 companies in total, including Arbutus Biopharma Corp (ABUS) , Sio Gene Therapies Inc (SIOX) , and Myovant Sciences Ltd (MYOV) among others .
Click here to see the complete history of Dexxon Holdings Ltd.’s form 4 insider trades.
Insider Ownership Summary of Dexxon Holdings Ltd.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | 2016-07-08 | 10 percent owner |
| SIOX | Sio Gene Therapies Inc | 2019-03-18 | 10 percent owner |
| MYOV | Myovant Sciences Ltd | 2019-06-04 | 10 percent owner |
| UROV | Urovant Sciences Ltd | 2019-07-10 | other: See remarks |
| ROIV | Roivant Sciences Ltd | 2021-10-01 | 10 percent owner |
Dexxon Holdings Ltd. Latest Holdings Summary
Dexxon Holdings Ltd. currently owns a total of 3 stocks. Among these stocks, Dexxon Holdings Ltd. owns 40,765,599 shares of Myovant Sciences Ltd (MYOV) as of June 4, 2019, with a value of $1.1 Billion and a weighting of 74.44%. Dexxon Holdings Ltd. owns 22,860,013 shares of Urovant Sciences Ltd (UROV) as of June 19, 2019, with a value of $371 Million and a weighting of 25.13%. Dexxon Holdings Ltd. also owns 13,244,048 shares of Sio Gene Therapies Inc (SIOX) as of March 18, 2019, with a value of $6 Million and a weighting of 0.43%.
Latest Holdings of Dexxon Holdings Ltd.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MYOV | Myovant Sciences Ltd | 2019-06-04 | 40,765,599 | 26.98 | 1,099,855,861 |
| UROV | Urovant Sciences Ltd | 2019-06-19 | 22,860,013 | 16.24 | 371,246,611 |
| SIOX | Sio Gene Therapies Inc | 2019-03-18 | 13,244,048 | 0.48 | 6,330,655 |
Holding Weightings of Dexxon Holdings Ltd.
Dexxon Holdings Ltd. Form 4 Trading Tracker
According to the SEC Form 4 filings, Dexxon Holdings Ltd. has made a total of 1 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Myovant Sciences Ltd is the acquisition of 2,424,242 shares on June 4, 2019, which cost Dexxon Holdings Ltd. around $20 Million.
According to the SEC Form 4 filings, Dexxon Holdings Ltd. has made a total of 10 transactions in Urovant Sciences Ltd (UROV) over the past 5 years, including 10 buys and 0 sells. The most-recent trade in Urovant Sciences Ltd is the acquisition of 18,204 shares on June 19, 2019, which cost Dexxon Holdings Ltd. around $151,457.
According to the SEC Form 4 filings, Dexxon Holdings Ltd. has made a total of 0 transactions in Sio Gene Therapies Inc (SIOX) over the past 5 years. The most-recent trade in Sio Gene Therapies Inc is the acquisition of 833,333 shares on March 18, 2019, which cost Dexxon Holdings Ltd. around $10 Million.
Insider Trading History of Dexxon Holdings Ltd.
- 1
Dexxon Holdings Ltd. Trading Performance
GuruFocus tracks the stock performance after each of Dexxon Holdings Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dexxon Holdings Ltd. is 4.83%. GuruFocus also compares Dexxon Holdings Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Dexxon Holdings Ltd. within 3 months outperforms 10 times out of 16 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Dexxon Holdings Ltd.'s insider trading performs compared to the benchmark.
Performance of Dexxon Holdings Ltd.
Average Return
9.24%
Outperforming Transactions
75%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 2.73 | 4.83 | 29.31 | 9.24 | -22.8 | -29.4 |
| Relative Return to S&P 500(%) | -0.54 | 1.82 | 20.38 | 3.08 | -35.34 | -46.05 |
Dexxon Holdings Ltd. Ownership Network
Ownership Network List of Dexxon Holdings Ltd.
Ownership Network Relation of Dexxon Holdings Ltd.
Dexxon Holdings Ltd. Owned Company Details
What does Arbutus Biopharma Corp do?
Who are the key executives at Arbutus Biopharma Corp?
Dexxon Holdings Ltd. is the 10 percent owner of Arbutus Biopharma Corp. Other key executives at Arbutus Biopharma Corp include Chief Financial Officer David C Hastings , Chief Business Officer Michael J. Mcelhaugh , and Chief Scientific Officer Michael J. Sofia .
Arbutus Biopharma Corp (ABUS) Insider Trades Summary
Over the past 18 months, Dexxon Holdings Ltd. made no insider transaction in Arbutus Biopharma Corp (ABUS). Other recent insider transactions involving Arbutus Biopharma Corp (ABUS) include a net sale of 10,164 shares made by Michael J. Mcelhaugh , a net sale of 9,982 shares made by Michael J. Sofia , and a net sale of 9,593 shares made by David C Hastings .
In summary, during the past 3 months, insiders sold 34,097 shares of Arbutus Biopharma Corp (ABUS) in total and bought 0 shares, with a net sale of 34,097 shares. During the past 18 months, 34,097 shares of Arbutus Biopharma Corp (ABUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 34,097 shares.
Arbutus Biopharma Corp (ABUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arbutus Biopharma Corp Insider Transactions
Dexxon Holdings Ltd. Mailing Address
Above is the net worth, insider trading, and ownership report for Dexxon Holdings Ltd.. You might contact Dexxon Holdings Ltd. via mailing address: 1 Dexcel Street, Or Akiva L3 30600000.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
